SEC Form 10-Q filed by GRAIL Inc.

MENLO PARK, Calif., Nov. 19, 2024 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will participate in the following investor conferences. Piper Sandler 36th Annual Healthcare Conference in New York, NY: fireside chat on Tuesday, Dec. 3 at 1:30 p.m. ET7th Annual Evercore ISI HealthCONx Conference in Coral Gables, Fla.: fireside chat on Wednesday, Dec. 4 at 3:50 p.m. ETLive and replay webcasts may be accessed in the investor relations section of GRAIL's website a

MENLO PARK, Calif., Nov. 18, 2024  /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the first patient has been tested for eligibility with the investigational GRAIL Non-Small Cell Lung Cancer (NSCLC) ctDNA Assay in the global TROPION-Lung12 Phase 3 study evaluating adjuvant treatment regimens in patients with Stage I adenocarcinoma NSCLC. The study is sponsored by AstraZeneca (NASDAQ:AZN) in collaboration with Daiichi Sankyo (TSE: 4568). The study, which is being conducted under a

Galleri Revenue Grew 52% Year-Over-Year to $25.4 Million Commercial Galleri Sales Surpassed 250,000 Tests Since Launch Cash Balance of $853.6 Million Provides Runway Into 2028 MENLO PARK, Calif., Nov. 12, 2024 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the third quarter 2024. Revenue in the third quarter was $28.7 million, representing 38% growth year over year, and revenue for Galleri was $25.4 million, representing 52% growth year over year. Ne

4 - GRAIL, Inc. (0001699031) (Issuer)

4 - GRAIL, Inc. (0001699031) (Issuer)

4 - GRAIL, Inc. (0001699031) (Issuer)

Wolfe Research initiated coverage of GRAIL with a rating of Peer Perform

Guggenheim initiated coverage of GRAIL with a rating of Neutral

4 - GRAIL, Inc. (0001699031) (Issuer)

SC 13G - GRAIL, Inc. (0001699031) (Subject)

SC 13G - GRAIL, Inc. (0001699031) (Subject)

SC 13G/A - GRAIL, Inc. (0001699031) (Subject)

10-Q - GRAIL, Inc. (0001699031) (Filer)

8-K - GRAIL, Inc. (0001699031) (Filer)

8-K - GRAIL, Inc. (0001699031) (Filer)

Galleri Revenue Grew 52% Year-Over-Year to $25.4 Million Commercial Galleri Sales Surpassed 250,000 Tests Since Launch Cash Balance of $853.6 Million Provides Runway Into 2028 MENLO PARK, Calif., Nov. 12, 2024 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the third quarter 2024. Revenue in the third quarter was $28.7 million, representing 38% growth year over year, and revenue for Galleri was $25.4 million, representing 52% growth year over year. Ne

MENLO PARK, Calif., Oct. 29, 2024 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the third quarter 2024 following the close of market on Tuesday, Nov. 12, 2024. Following the release, company management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss results and business progress. Third Quarter 2024 Webcast and Conference Call DetailsA link to the live webcast and recorded replay will be available at the inves

Second Quarter Revenue Grew 43% Year-Over-Year to $32.0 Million Portfolio Prioritization and Corporate Restructure Extends Cash Runway into 2028 MENLO PARK, Calif., Aug. 13, 2024 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the second quarter 2024. Revenue in the second quarter was $32.0 million, representing 43% growth year over year. Net loss for the quarter, which includes amortization and impairment of acquisition-related intangible items, was

MENLO PARK, Calif., Oct. 21, 2024 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced the appointment of Sarah Krevans to its Board of Directors, effective immediately. Ms. Krevans will also serve as a member of the Board's Audit Committee, Compensation Committee, and Nominating and Governance Committee. Following the appointment of Ms. Krevans, the Board will be composed of five directors, four of whom are independent. Ms. Krevans served as president and CEO of Sutter Health, a Northern

Veteran Leader Brings Deep Strategic, Aviation, and Governance Experience to Boardroom ATLANTA, Aug. 8, 2024 /PRNewswire/ -- Wheels Up Experience Inc. (NYSE:UP) today announced that Gregory L. Summe, Managing Partner of Glen Capital Partners LLC, joined its Board of Directors, effective August 7. Summe fills the unexpired term of David Adelman, who is stepping down to focus on other professional pursuits. Summe's initial term as a Class II director will continue until the 2026 annual meeting of the Company's stockholders. He will serve on the Audit and Compensation Committees

Community Health Network Has Begun Enrollment of the Prospective, Multi-Center Study to Assess the Real-World Clinical Impact of Galleri® in Addition to Currently Recommended Cancer ScreeningsStudy Enrollment Includes Focus on Diverse and Underrepresented PopulationsCosts of Galleri and Related Items and Services for Study Participants Will be Covered by Medicare

Community Health Network Has Begun Enrollment of the Prospective, Multi-Center Study to Assess the Real-World Clinical Impact of Galleri® in Addition to Currently Recommended Cancer ScreeningsStudy Enrollment Includes Focus on Diverse and Underrepresented PopulationsCosts of Galleri and Related Items and Services for Study Participants Will be Covered by MedicareMENLO PARK, Calif., July 18, 2024 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the first participant has been enrolled in the REACH/Galleri-Medicare study at Community Health Network, a leading integrated healthcare system in central

Wall Street continues to experience a series of memorable days, with the bulls riding the rally with increasing confidence, certain that the Federal Reserve will begin cutting interest rates in September. Fed futures currently indicate a 100% probability that policymakers will cut interest rates in two months, according to the CME Group‘s FedWatch tool. This time, blue-chip stocks and gold are stealing the spotlight by breaking their all-time highs, while small caps, as tracked by the iShares Russell 2000 ETF (NYSE:IWM), have posted their fifth consecutive day in the green, marking their best five-day rally in over four years. The Dow Jones Industrial Average surged to 40,800 points